CoChat

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Lovastatin Treatment Inducing Apoptosis in Human Pancreatic Cancer Cells by Inhibiting Cholesterol Rafts in Plasma Membrane and Mitochondria

Open access
Gyoten, Momoko, Luo, Yi, Fujiwara-Tani, Rina, Mori, Shiori, Ogata, Ruiko, Kishi, Shingo, Kuniyasu, Hiroki · 2023 · International Journal of Molecular Sciences

Abstract

Resistance to anticancer drugs is a problem in the treatment of pancreatic ductal carcinoma (PDAC) and overcoming it is an important issue. Recently, it has been reported that statins induce apoptosis in cancer cells but the mechanism has not been completely elucidated. We investigated the antitumor mechanisms of statins against PDAC and their impact on resistance to gemcitabine (GEM). Lovastatin (LOVA) increased mitochondrial oxidative stress in PDAC cells, leading to apoptosis. LOVA reduced lipid rafts in the plasma membrane and mitochondria, suppressed the activation of epithelial growth factor receptor (EGFR) and AKT in plasma membrane rafts, and reduced B-cell lymphoma 2 (BCL2)-Bcl-2-associated X protein (BAX) binding and the translocation of F1F0 ATPase in mitochondrial rafts. In the three GEM-resistant cell lines derived from MIA and PANC1, the lipid rafts in the cell membrane and the mitochondria were increased to activate EGFR and AKT and to increase BCL2-BAX binding, which suppressed apoptosis. LOVA abrogated these anti-apoptotic effects by reducing the rafts in the resistant cells. By treating the resistant cells with LOVA, GEM sensitivity improved to the level of the parental cells. Therefore, cholesterol rafts contribute to drug resistance in PDAC. Further clinical research is warranted on overcoming anticancer drug resistance by statin-mediated intracellular cholesterol regulation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms242316814

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Effect of statins on PDAC cells. (A) Effects of statins on PDAC cell proliferation. (B) The inhibitory effect of statins on HMG-CoA reductase activity. (C) Correlation between HMG-CoA reductase inhibitory activity and growth inhibition by statins. (D–F) Effects of LOVA on invasion (D), sphere formation (E), and GEM sensitivity (F). Error bars: standard deviation from three independent trials. Statistical significance was calculated using the Mann–Whitney U test. PDAC, pancreatic ductal adenocarcinoma; MIA, MIA-PaCa-2; C, control; LOVA, lovastatin; SIMVA, simvastatin; FLUVA, fluvastatin; ROUSVA, rosuvastatin; HMGCR, 3-hydroxy-3-methylglutaryl coenzyme A reductase; GEM, gemcitabine.
Figure 1 Effect of statins on PDAC cells. (A) Effects of statins on PDAC cell proliferation. (B) The inhibitory effect of statins on HMG-CoA reductase activity. (C) Correlation between HMG-CoA reductase inhibitory activity and growth inhibition by statins. (D–F) Effects of LOVA on invasion (D), sphere formation (E), and GEM sensitivity (F). Error bars: standard deviation from three independent trials. Statistical significance was calculated using the Mann–Whitney U test. PDAC, pancreatic ductal adenocarcinoma; MIA, MIA-PaCa-2; C, control; LOVA, lovastatin; SIMVA, simvastatin; FLUVA, fluvastatin; ROUSVA, rosuvastatin; HMGCR, 3-hydroxy-3-methylglutaryl coenzyme A reductase; GEM, gemcitabine.CC BY · PubMed Central
Figure 2 Effect of LOVA on induction of apoptosis. (A–C) Effect of LOVA on mitochondrial oxidative stress (A,B), mitochondrial volume, and membrane potential (A,C). Scale bar, 50 μm. (D) DNA ladder formation (left) and PARP cleavage by LOVA. (E) Inhibition of cell death. Error bars: standard deviation from three independent trials. Statistical significance was calculated using the Mann–Whitney U test. PDAC, pancreatic ductal adenocarcinoma; MIA, MIA-PaCa-2; C, control; LOVA, lovastatin; SO, superoxide; HR, hydroxy radical; HP, hydrogen peroxide; MV, mitochondrial volume; MMP, mitochondrial membrane potential; PARP, poly (ADP-ribose) polymerase; ZVAD, Z-VAD-FMK; NEC, necrostatin; FRS, ferrostatin; NAC, N-acetyl-L-cysteine; SAL, salubrinal; CHL, chloroquine.
Figure 2 Effect of LOVA on induction of apoptosis. (A–C) Effect of LOVA on mitochondrial oxidative stress (A,B), mitochondrial volume, and membrane potential (A,C). Scale bar, 50 μm. (D) DNA ladder formation (left) and PARP cleavage by LOVA. (E) Inhibition of cell death. Error bars: standard deviation from three independent trials. Statistical significance was calculated using the Mann–Whitney U test. PDAC, pancreatic ductal adenocarcinoma; MIA, MIA-PaCa-2; C, control; LOVA, lovastatin; SO, superoxide; HR, hydroxy radical; HP, hydrogen peroxide; MV, mitochondrial volume; MMP, mitochondrial membrane potential; PARP, poly (ADP-ribose) polymerase; ZVAD, Z-VAD-FMK; NEC, necrostatin; FRS, ferrostatin; NAC, N-acetyl-L-cysteine; SAL, salubrinal; CHL, chloroquine.CC BY · PubMed Central
Figure 3 Effect of LOVA on plasma membrane raft. (A) Plasma membrane cholesterol content. (B) Lipid raft content of the plasma membrane. (C,D) Effect of LOVA on the activation of EGFR and AKT in whole-cell lysates (C) and plasma membrane raft fractions (D) (Right panels) Semiquantification of Western blot. (E) The effect of LOVA on the interaction between PI3K and AKT in plasma membrane rafts. (Right panel) Semiquantification of Western blot. (F) Effect of LOVA on turnover of membranous EGFR. Error bars: standard deviation from three independent trials. Statistical significance was calculated using the Mann–Whitney U test. PDAC, pancreatic ductal adenocarcinoma; MIA, MIA-PaCa-2; C, control; LOVA, lovastatin; EGFR, epithelial growth factor receptor; pEGFR, phosphorylated EGFR; pAKT, phosphorylated AKT; PI3K, phosphoinositide 3-kinases; WCL, whole-cell lysate; IP, immunoprecipitation; HC, heavy chain; CB, Coomassie blue.
Figure 3 Effect of LOVA on plasma membrane raft. (A) Plasma membrane cholesterol content. (B) Lipid raft content of the plasma membrane. (C,D) Effect of LOVA on the activation of EGFR and AKT in whole-cell lysates (C) and plasma membrane raft fractions (D) (Right panels) Semiquantification of Western blot. (E) The effect of LOVA on the interaction between PI3K and AKT in plasma membrane rafts. (Right panel) Semiquantification of Western blot. (F) Effect of LOVA on turnover of membranous EGFR. Error bars: standard deviation from three independent trials. Statistical significance was calculated using the Mann–Whitney U test. PDAC, pancreatic ductal adenocarcinoma; MIA, MIA-PaCa-2; C, control; LOVA, lovastatin; EGFR, epithelial growth factor receptor; pEGFR, phosphorylated EGFR; pAKT, phosphorylated AKT; PI3K, phosphoinositide 3-kinases; WCL, whole-cell lysate; IP, immunoprecipitation; HC, heavy chain; CB, Coomassie blue.CC BY · PubMed Central
Figure 4 Effect of LOVA on mitochondrial raft. (A) Cholesterol content in mitochondria. (B) Lipid raft content in the mitochondria. (C,D) Effect of LOVA on mitochondrial raft proteins (C) and BCL2-BAX binding in mitochondrial rafts. (Right panels) Semiquantification of Western blot. (D) Error bars: standard deviation from three independent trials. Statistical significance was calculated using the Mann–Whitney U test. PDAC, pancreatic ductal adenocarcinoma; MIA, MIA-PaCa-2; C, control; LOVA, lovastatin; BCL2, B-cell lymphoma 2; BAX, Bcl-2-associated X protein; F1F0, F1F0 ATP synthase subunit C; cholera T, cholera toxin subunit B CF®Dye; IP, immunoprecipitation; HC, heavy chain; CB, Coomassie blue.
Figure 4 Effect of LOVA on mitochondrial raft. (A) Cholesterol content in mitochondria. (B) Lipid raft content in the mitochondria. (C,D) Effect of LOVA on mitochondrial raft proteins (C) and BCL2-BAX binding in mitochondrial rafts. (Right panels) Semiquantification of Western blot. (D) Error bars: standard deviation from three independent trials. Statistical significance was calculated using the Mann–Whitney U test. PDAC, pancreatic ductal adenocarcinoma; MIA, MIA-PaCa-2; C, control; LOVA, lovastatin; BCL2, B-cell lymphoma 2; BAX, Bcl-2-associated X protein; F1F0, F1F0 ATP synthase subunit C; cholera T, cholera toxin subunit B CF®Dye; IP, immunoprecipitation; HC, heavy chain; CB, Coomassie blue.CC BY · PubMed Central
Figure 5 Effect of MβCD on PDAC cells. (A) Apoptosis (B) Lipid raft content of the plasma membrane. (C) Effect of LOVA on the activation of EGFR and AKT in plasma membrane rafts. (Right panel) Semiquantification of Western blot. (D) Effect of LOVA on mitochondrial raft proteins. Error bars: standard deviation from three independent trials. (Right panel) Semiquantification of Western blot. Statistical significance was calculated using the Mann–Whitney U test. PDAC, pancreatic ductal adenocarcinoma; MIA, MIA-PaCa-2; C, control; LOVA, lovastatin; MbCD, methyl-β-cyclodextrin; EGFR, epithelial growth factor receptor; pEGFR, phosphorylated EGFR; pAKT, phosphorylated AKT; PI3K, phosphoinositide 3-kinases; BCL2, B-cell lymphoma 2; BAX, Bcl-2-associated X protein; F1F0, F1F0 ATP synthase subunit C.
Figure 5 Effect of MβCD on PDAC cells. (A) Apoptosis (B) Lipid raft content of the plasma membrane. (C) Effect of LOVA on the activation of EGFR and AKT in plasma membrane rafts. (Right panel) Semiquantification of Western blot. (D) Effect of LOVA on mitochondrial raft proteins. Error bars: standard deviation from three independent trials. (Right panel) Semiquantification of Western blot. Statistical significance was calculated using the Mann–Whitney U test. PDAC, pancreatic ductal adenocarcinoma; MIA, MIA-PaCa-2; C, control; LOVA, lovastatin; MbCD, methyl-β-cyclodextrin; EGFR, epithelial growth factor receptor; pEGFR, phosphorylated EGFR; pAKT, phosphorylated AKT; PI3K, phosphoinositide 3-kinases; BCL2, B-cell lymphoma 2; BAX, Bcl-2-associated X protein; F1F0, F1F0 ATP synthase subunit C.CC BY · PubMed Central
Figure 6 Expression of raft-associated proteins in human GEM-resistant PDAC cells. (A) Cholesterol and raft content in the plasma membrane and mitochondria. (B) Thapsigargin-induced apoptosis. (C) Activation of EGFR and AKT in the plasma membrane raft fraction of GEM-resistant PDAC cells. (Right panel) Semiquantification of Western blot. (D) Raft proteins in the mitochondria and BCL2-BAX binding in mitochondrial rafts. (Right panel) Semiquantification of Western blot. Statistical significance was calculated using the Mann–Whitney U test. PDAC, pancreatic ductal adenocarcinoma; MIA, MIA-PaCa-2; C, control; LOVA, lovastatin; EGFR, epithelial growth factor receptor; pEGFR, phosphorylated EGFR; pAKT, phosphorylated AKT; PI3K, phosphoinositide 3-kinases; BCL2, B-cell lymphoma 2; BAX, Bcl-2-associated X protein; F1F0, F1F0 ATP synthase subunit C; GEM, gemcitabine.
Figure 6 Expression of raft-associated proteins in human GEM-resistant PDAC cells. (A) Cholesterol and raft content in the plasma membrane and mitochondria. (B) Thapsigargin-induced apoptosis. (C) Activation of EGFR and AKT in the plasma membrane raft fraction of GEM-resistant PDAC cells. (Right panel) Semiquantification of Western blot. (D) Raft proteins in the mitochondria and BCL2-BAX binding in mitochondrial rafts. (Right panel) Semiquantification of Western blot. Statistical significance was calculated using the Mann–Whitney U test. PDAC, pancreatic ductal adenocarcinoma; MIA, MIA-PaCa-2; C, control; LOVA, lovastatin; EGFR, epithelial growth factor receptor; pEGFR, phosphorylated EGFR; pAKT, phosphorylated AKT; PI3K, phosphoinositide 3-kinases; BCL2, B-cell lymphoma 2; BAX, Bcl-2-associated X protein; F1F0, F1F0 ATP synthase subunit C; GEM, gemcitabine.CC BY · PubMed Central
Figure 7 Effect of LOVA on GEM sensitivity in human GEM-resistant PDAC cells. (A) GEM sensitivity in GEM-resistant PDAC cell lines without LOVA (left) or with LOVA (right). (B) Effect of LOVA on EGFR and AKT activation in the plasma membrane raft fraction. (Right panel) Semiquantification of Western blot. (C) Effect of LOVA on mitochondrial raft proteins and BCL2-BAX binding in mitochondrial rafts. (Right panel) Semiquantification of Western blot. Error bars: standard deviation from three independent trials. Statistical significance was calculated using the Mann–Whitney U test. PDAC, pancreatic ductal adenocarcinoma; MIA, MIA-PaCa-2; C, control; LOVA, lovastatin; EGFR, epithelial growth factor receptor; pEGFR, phosphorylated EGFR; pAKT, phosphorylated AKT; PI3K, phosphoinositide 3-kinases; BCL2, B-cell lymphoma 2; BAX, Bcl-2-associated X protein; F1F0, F1F0 ATP synthase subunit C; GEM, gemcitabine.
Figure 7 Effect of LOVA on GEM sensitivity in human GEM-resistant PDAC cells. (A) GEM sensitivity in GEM-resistant PDAC cell lines without LOVA (left) or with LOVA (right). (B) Effect of LOVA on EGFR and AKT activation in the plasma membrane raft fraction. (Right panel) Semiquantification of Western blot. (C) Effect of LOVA on mitochondrial raft proteins and BCL2-BAX binding in mitochondrial rafts. (Right panel) Semiquantification of Western blot. Error bars: standard deviation from three independent trials. Statistical significance was calculated using the Mann–Whitney U test. PDAC, pancreatic ductal adenocarcinoma; MIA, MIA-PaCa-2; C, control; LOVA, lovastatin; EGFR, epithelial growth factor receptor; pEGFR, phosphorylated EGFR; pAKT, phosphorylated AKT; PI3K, phosphoinositide 3-kinases; BCL2, B-cell lymphoma 2; BAX, Bcl-2-associated X protein; F1F0, F1F0 ATP synthase subunit C; GEM, gemcitabine.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 30

Metadata

Authors
Gyoten, M., Luo, Y., Fujiwara-Tani, R., Mori, S., Ogata, R., Kishi, S., & Kuniyasu, H.
Affiliations
  • Nara Medical University (JP)
  • Nantong University (CN)
  • Department of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Nara, Japan
  • Nozaki Tokushukai Hospital (JP)
Corresponding author
Kuniyasu, Hiroki
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2023-11-27
Volume
24
Issue
23
Pages
16814
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4389048098
Cited by
28
References
40
Citations by year
2026: 9 · 2025: 16 · 2024: 3
FWCI
3.55
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
MEXT KAKENHI (19K16564, 20K21659, 23K16621, 23K19900)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Caveolin-1 and cellular processes
Keywords
lovastatin, statins, pancreatic ductal carcinoma, apoptosis, lipid rafts, gemcitabine resistance, mitochondrial oxidative stress, EGFR, Akt, chemoresistance
MeSH terms
Gemcitabine, Antineoplastic Agents, Cell Membrane, Cholesterol, Humans, Lovastatin, Mitochondria, Pancreatic Neoplasms, Apoptosis, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Carcinoma, Pancreatic Ductal, Membrane Microdomains, Cell Line, Tumor, bcl-2-Associated X Protein, Proto-Oncogene Proteins c-akt, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lovastatin Treatment Inducing Apoptosis in Human Pancreatic Cancer Cells by Inhibiting Cholesterol Rafts in Plasma Membrane and Mitochondria. https://app.cochat.ai/papers/10.3390/ijms242316814
The paper
Gyoten, M., Luo, Y., Fujiwara-Tani, R., Mori, S., Ogata, R., Kishi, S., & Kuniyasu, H. (2023). Lovastatin Treatment Inducing Apoptosis in Human Pancreatic Cancer Cells by Inhibiting Cholesterol Rafts in Plasma Membrane and Mitochondria. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242316814

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.